12:00 AM
Dec 04, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Status

ALT-711: Completed Phase IIa trial

Alteon Inc. (ALT), Ramsey, N.J.
Product: ALT-711
Business: Metabolic
Therapeutic category: Metabolism
Target: A.G.E.s
Description: Advanced Glycosylation End-product (A.G.E.) crosslink...

Read the full 86 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >